バイオエンジニアリングタンパク質医薬品の世界市場レポート 2025年

バイオエンジニアリングタンパク質医薬品市場規模は、今後数年間で力強い成長が見込まれます。2029年には年間平均成長率（CAGR）8.3％で6,044億2,000万米ドルに成長します。予測期間の成長は、個別化医療の動向、治療用途の拡大、新興国市場、希少疾患への注力、ヘルスケアインフラの整備などに起因すると考えられます。予測期間における主な動向には、タンパク質工学の進歩、モノクローナル抗体への注目の高まり、個別化医療と標的治療、次世代生物製剤の出現、製造プロセスの最適化などがあります。

慢性疾患の有病率の上昇は、今後のバイオ医薬品市場の成長を牽引すると予測されます。慢性疾患とは、1年以上持続し、継続的な治療が必要で、日常的な身体活動が制限される疾患と定義されます。慢性疾患の治療には、コンビナトリアルかつ論理的な手法により、腫瘍学や再生医療にデザイナー・タンパク質療法が活用されています。例えば、2022年9月、世界保健機関（WHO）は2022年ハイライトの中で、非感染性疾患（NCDs）による世界の年間死亡者数は4,100万人で、世界の死亡者数の74％を占めると報告しました。このうち、1,790万人が心血管疾患、930万人ががん、410万人が慢性呼吸器疾患、200万人が糖尿病による死亡です。このように、慢性疾患の罹患率の増加がバイオエンジニアリングタンパク質医薬品の成長に拍車をかけています。

ヘルスケア支出の増加は、今後のバイオエンジニアリングタンパク質医薬品市場の成長を促進すると予測されています。ヘルスケア支出とは、特定の期間にヘルスケア商品およびサービスに費やされる金銭的総額のことで、治療、投薬、病院での治療、その他の健康関連サービスに関連する費用が含まれます。バイオエンジニアリングタンパク質医薬品は的を絞った革新的な治療法を提供し、投薬、病院での治療、様々な医療サービスに関連する医療費全体に貢献しています。バイオエンジニアリングタンパク質医薬品の利用率の増加は、ヘルスケア支出全体の増加につながります。例えば、2022年11月、カナダ健康情報研究所（CIHI）は、カナダの総医療費は0.8％増加し、2021年の3,280億米ドルから2022年には3,310億米ドルに増加すると予測しました。したがって、医療費の伸びがバイオエンジニアリングタンパク質医薬品市場を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界バイオエンジニアリングタンパク質医薬品 PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のバイオエンジニアリングタンパク質医薬品市場：成長率分析
• 世界のバイオエンジニアリングタンパク質医薬品市場の実績：規模と成長, 2019-2024
• 世界のバイオエンジニアリングタンパク質医薬品市場の予測：規模と成長, 2024-2029, 2034F
• 世界バイオエンジニアリングタンパク質医薬品総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のバイオエンジニアリングタンパク質医薬品市場薬の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 組み換えタンパク質
• ワクチン
• ペプチド抗生物質
• 治療用酵素
• その他の薬剤の種類
• 世界のバイオエンジニアリングタンパク質医薬品市場：技術別、実績と予測, 2019-2024, 2024-2029F, 2034F
• バイオリアクター
• 分別
• 遺伝子組み換え生物
• 遺伝子工学
• ファーミング
• 細胞培養
• 微生物細胞発酵
• その他のテクノロジー
• 世界のバイオエンジニアリングタンパク質医薬品市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 自己免疫
• 心臓
• 先天性
• 感染症
• がん
• 糖尿病
• 関節炎
• その他のアプリケーション
• 世界のバイオエンジニアリングタンパク質医薬品市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 製薬
• 契約調査機関
• 調査機関
• バイオテクノロジー企業
• 世界のバイオエンジニアリングタンパク質医薬品市場、組み換えタンパク質のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• モノクローナル抗体
• ホルモン
• サイトカイン
• 世界のバイオエンジニアリングタンパク質医薬品市場、ワクチンの種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 組み換えワクチン
• DNAワクチン
• 世界のバイオエンジニアリングタンパク質医薬品市場ペプチド抗生物質の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• リポペプチド抗生物質
• 糖ペプチド抗生物質
• 世界のバイオエンジニアリングタンパク質医薬品市場、治療用酵素のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 酵素補充療法
• バイオシミラー酵素
• 世界のバイオエンジニアリングタンパク質医薬品市場、その他の薬剤タイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 融合タンパク質
• 抗体薬物複合体（ADC）

第7章 地域別・国別分析

• 世界のバイオエンジニアリングタンパク質医薬品市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のバイオエンジニアリングタンパク質医薬品市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• バイオエンジニアリングタンパク質医薬品市場：競合情勢
• バイオエンジニアリングタンパク質医薬品市場：企業プロファイル
  • Abbvie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • Bayer HealthCare Pharmaceuticals LLC Overview, Products and Services, Strategy and Financial Analysis
  • Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• F. Hoffmann-La Roche AG
• GlaxoSmithKline plc
• Johnson & Johnson
• Novartis AG
• Novo Nordisk A/S
• Sanofi S.A.
• Grifols S.A.
• Adma Biologics Inc.
• CSL Limited
• Abbott Laboratories
• Baxter International Inc.
• Fresenius Kabi AG
• Merck & Co. Inc.
• Pfizer Inc.
• Biogen Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• バイオエンジニアリングタンパク質医薬品市場2029：新たな機会を提供する国
• バイオエンジニアリングタンパク質医薬品市場2029：新たな機会を提供するセグメント
• バイオエンジニアリングタンパク質医薬品市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Bioengineered protein drugs encompass medications manufactured using laboratory techniques involving living cells, leveraging biological processes and protein molecules. This methodology enables precise manipulation of mechanical and stimuli-responsive characteristics, ensuring high purity and consistent molecular weight, thereby mitigating adverse effects.

The primary categories of bioengineered protein drugs include recombinant proteins, vaccines, peptide antibiotics, therapeutic enzymes, among others. Recombinant proteins are generated via genetic engineering methods, where genes encoding desired proteins are inserted into organisms such as bacteria or yeast. These proteins are produced utilizing diverse technologies such as bioreactors, microbial cell fermentation, fractionation, genetically modified organisms, genetic engineering, pharmacology, cell culture, among others, employed by pharmaceutical firms, contract research organizations, research institutes, and biotech companies. These bioengineered proteins find application in treating a spectrum of diseases, encompassing autoimmune, cardiovascular, congenital, infectious, oncological, diabetic, arthritic, and other conditions.

The bioengineered protein drugs market research report is one of a series of new reports from The Business Research Company that provides bioengineered protein drugs market statistics, including global market size, regional shares, competitors with a bioengineered protein drugs market share, detailed bioengineered protein drugs market segments, market trends and opportunities, and any further data you may need to thrive in the bioengineered protein drugs industry. This bioengineered protein drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The bioengineered protein drugs market size has grown strongly in recent years. It will grow from$406.39 billion in 2024 to $439.29 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to increased understanding of diseases, regulatory approvals, rising prevalence of chronic diseases, collaborations and partnership, market expansion

The bioengineered protein drugs market size is expected to see strong growth in the next few years. It will grow to $604.42 billion in 2029 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to personalized medicine trends, expanding therapeutic applications, emerging markets, focus on rare diseases, healthcare infrastructure development. Major trends in the forecast period include advancements in protein engineering, increased focus on monoclonal antibodies, personalized medicine and targeted therapies, emergence of next-generation biologics, manufacturing process optimization.

The rising prevalence of chronic diseases is projected to drive the growth of the bioengineered protein drug market in the future. Chronic diseases are defined as illnesses that persist for a year or longer, necessitate continuous medical care, and limit daily physical activities. Bioengineered protein drugs are utilized for treating chronic diseases, employing designer protein therapies in oncology and regenerative medicine through combinatorial and logical methodologies. For instance, in September 2022, the World Health Organization (WHO) reported in its 2022 Highlights that there were 41 million deaths annually worldwide due to noncommunicable diseases (NCDs), which account for 74% of global deaths. Among these, 17.9 million deaths were attributed to cardiovascular diseases, 9.3 million to cancer, 4.1 million to chronic respiratory diseases, and 2.0 million to diabetes. Thus, the increasing incidence of chronic diseases is fueling the growth of bioengineered protein drugs.

The increasing healthcare expenditure is projected to drive the growth of the bioengineered protein drugs market in the future. Healthcare expenditure refers to the total monetary amount spent on healthcare goods and services over a specific period, including costs associated with medical treatments, medications, hospital care, and other health-related services. Bioengineered protein drugs offer targeted and innovative therapies that contribute to the overall healthcare expenses related to medications, hospital care, and various health services. The rising utilization of bioengineered protein drugs leads to an increase in overall healthcare spending. For example, in November 2022, the Canadian Institute for Health Information (CIHI) forecasted that total health spending in Canada would increase by 0.8%, rising from $328 billion in 2021 to $331 billion in 2022. Therefore, the growth in healthcare expenditure is driving the bioengineered protein drugs market.

Major companies in the bioengineered protein drug market are increasingly forming strategic partnerships to deliver essential bioengineered protein drugs to businesses and governments. Strategic partnerships involve companies utilizing each other's strengths and resources to achieve mutual benefits and success. For example, in June 2023, Future Fields, a biotechnology company based in Canada, collaborated with Jenthera Therapeutics, another Canadian biotech firm focused on creating innovative therapies for rare and complex diseases. Through this partnership, they aim to develop a novel cancer-fighting protein using Future Fields' EntoEngine platform, which is designed for cost-effective and sustainable mass production.

Major companies in the bioengineered protein drugs market are concentrating on developing innovative solutions, such as tissue therapeutics platforms, to meet the unmet needs in regenerative medicine. A tissue therapeutics platform is a technology designed for the creation of bioengineered tissues that can be used in regenerative medicine. For example, in April 2022, Satellite Bio, a U.S.-based developer of therapeutic platforms, introduced the Satellite Adaptive Tissue (SAT) platform. This innovative tissue therapeutics technology utilizes the SAT platform to produce bioengineered tissues. The goal of these implantable therapies is to repair, restore, or replace dysfunctional organs.

In September 2024, Ligand Pharmaceuticals Inc., a biopharmaceutical company based in the United States, acquired Apeiron Biologics for $100 million. This acquisition is intended to enhance Ligand's portfolio by providing royalty rights to Qarziba (dinutuximab beta), the sole approved immunotherapy for high-risk neuroblastoma, which is currently available in more than 35 countries. Apeiron Biologics AG is an Austria-based biotechnology company dedicated to developing innovative immunotherapies for treating cancer and other diseases.

Major companies operating in the bioengineered protein drugs market include Abbvie Inc., Amgen Inc., Astrazeneca PLC, Bayer HealthCare Pharmaceuticals LLC, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Johnson & Johnson, Novartis AG, Novo Nordisk A/S, Sanofi S.A., Grifols S.A., Adma Biologics Inc., CSL Limited, Abbott Laboratories, Baxter International Inc., Fresenius Kabi AG, Merck & Co. Inc., Pfizer Inc., Biogen Inc., Bristol-Myers Squibb Company, Genentech Inc., Lonza Group AG, MedImmune LLC, Regeneron Pharmaceuticals Inc., Shire plc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Shanghai United Cell Biotechnology Co. Ltd., Panacea Biotec Ltd.

North America was the largest region in the bioengineered protein drugs market in 2024. The regions covered in the bioengineered protein drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the bioengineered protein drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The bioengineered protein drugs market consists of sales of cytokines, peptide antibiotics, monoclonal antibodies, replacement proteins, and blood products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Bioengineered Protein Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on bioengineered protein drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for bioengineered protein drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The bioengineered protein drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Recombinant Protein; Vaccine; Peptide Antibiotics; Therapeutic Enzymes; Other Drug Type
• 2) By Technology: Bioreactors; Fractionation; Genetically Modified Organisms; Genetic Engineering; Pharming; Cell Culture; Microbial Cell Fermentation; Other Technology
• 3) By Application: Autoimmune; Heart; Congenital; Infectious Diseases; Cancer; Diabetes; Arthritis; Other Application
• 4) By End User: Pharmaceutical; Contract Research Organizations; Research Institutes; Biotechnology Companies
• Subsegments:
• 1) By Recombinant Protein: Monoclonal Antibodies; Hormones; Cytokines
• 2) By Vaccine: Recombinant Vaccines; DNA Vaccines
• 3) By Peptide Antibiotics: Lipopeptide Antibiotics; Glycopeptide Antibiotics
• 4) By Therapeutic Enzymes: Enzyme Replacement Therapies; Biosimilar Enzymes
• 5) By Other Drug Type: Fusion Proteins; Antibody-Drug Conjugates (ADCs)
• Companies Mentioned: Abbvie Inc.; Amgen Inc.; Astrazeneca PLC; Bayer HealthCare Pharmaceuticals LLC; Eli Lilly and Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Bioengineered Protein Drugs Market Characteristics

3. Bioengineered Protein Drugs Market Trends And Strategies

4. Bioengineered Protein Drugs Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Bioengineered Protein Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Bioengineered Protein Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Bioengineered Protein Drugs Market Growth Rate Analysis
• 5.4. Global Bioengineered Protein Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Bioengineered Protein Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Bioengineered Protein Drugs Total Addressable Market (TAM)

6. Bioengineered Protein Drugs Market Segmentation

• 6.1. Global Bioengineered Protein Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Recombinant Protein
• Vaccine
• Peptide Antibiotics
• Therapeutic Enzymes
• Other Drug Type
• 6.2. Global Bioengineered Protein Drugs Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bioreactors
• Fractionation
• Genetically Modified Organisms
• Genetic Engineering
• Pharming
• Cell Culture
• Microbial Cell Fermentation
• Other Technology
• 6.3. Global Bioengineered Protein Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Autoimmune
• Heart
• Congenital
• Infectious Diseases
• Cancer
• Diabetes
• Arthritis
• Other Application
• 6.4. Global Bioengineered Protein Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pharmaceutical
• Contract Research Organizations
• Research Institutes
• Biotechnology Companies
• 6.5. Global Bioengineered Protein Drugs Market, Sub-Segmentation Of Recombinant Protein, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibodies
• Hormones
• Cytokines
• 6.6. Global Bioengineered Protein Drugs Market, Sub-Segmentation Of Vaccine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Recombinant Vaccines
• DNA Vaccines
• 6.7. Global Bioengineered Protein Drugs Market, Sub-Segmentation Of Peptide Antibiotics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lipopeptide Antibiotics
• Glycopeptide Antibiotics
• 6.8. Global Bioengineered Protein Drugs Market, Sub-Segmentation Of Therapeutic Enzymes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Enzyme Replacement Therapies
• Biosimilar Enzymes
• 6.9. Global Bioengineered Protein Drugs Market, Sub-Segmentation Of Other Drug Type, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fusion Proteins
• Antibody-Drug Conjugates (ADCs)

7. Bioengineered Protein Drugs Market Regional And Country Analysis

• 7.1. Global Bioengineered Protein Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Bioengineered Protein Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Bioengineered Protein Drugs Market

• 8.1. Asia-Pacific Bioengineered Protein Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Bioengineered Protein Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Bioengineered Protein Drugs Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Bioengineered Protein Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Bioengineered Protein Drugs Market

• 9.1. China Bioengineered Protein Drugs Market Overview
• 9.2. China Bioengineered Protein Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Bioengineered Protein Drugs Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Bioengineered Protein Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Bioengineered Protein Drugs Market

• 10.1. India Bioengineered Protein Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Bioengineered Protein Drugs Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Bioengineered Protein Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Bioengineered Protein Drugs Market

• 11.1. Japan Bioengineered Protein Drugs Market Overview
• 11.2. Japan Bioengineered Protein Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Bioengineered Protein Drugs Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Bioengineered Protein Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Bioengineered Protein Drugs Market

• 12.1. Australia Bioengineered Protein Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Bioengineered Protein Drugs Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Bioengineered Protein Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Bioengineered Protein Drugs Market

• 13.1. Indonesia Bioengineered Protein Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Bioengineered Protein Drugs Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Bioengineered Protein Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Bioengineered Protein Drugs Market

• 14.1. South Korea Bioengineered Protein Drugs Market Overview
• 14.2. South Korea Bioengineered Protein Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Bioengineered Protein Drugs Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Bioengineered Protein Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Bioengineered Protein Drugs Market

• 15.1. Western Europe Bioengineered Protein Drugs Market Overview
• 15.2. Western Europe Bioengineered Protein Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Bioengineered Protein Drugs Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Bioengineered Protein Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Bioengineered Protein Drugs Market

• 16.1. UK Bioengineered Protein Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Bioengineered Protein Drugs Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Bioengineered Protein Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Bioengineered Protein Drugs Market

• 17.1. Germany Bioengineered Protein Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Bioengineered Protein Drugs Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Bioengineered Protein Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Bioengineered Protein Drugs Market

• 18.1. France Bioengineered Protein Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Bioengineered Protein Drugs Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Bioengineered Protein Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Bioengineered Protein Drugs Market

• 19.1. Italy Bioengineered Protein Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Bioengineered Protein Drugs Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Bioengineered Protein Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Bioengineered Protein Drugs Market

• 20.1. Spain Bioengineered Protein Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Bioengineered Protein Drugs Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Bioengineered Protein Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Bioengineered Protein Drugs Market

• 21.1. Eastern Europe Bioengineered Protein Drugs Market Overview
• 21.2. Eastern Europe Bioengineered Protein Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Bioengineered Protein Drugs Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Bioengineered Protein Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Bioengineered Protein Drugs Market

• 22.1. Russia Bioengineered Protein Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Bioengineered Protein Drugs Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Bioengineered Protein Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Bioengineered Protein Drugs Market

• 23.1. North America Bioengineered Protein Drugs Market Overview
• 23.2. North America Bioengineered Protein Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Bioengineered Protein Drugs Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Bioengineered Protein Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Bioengineered Protein Drugs Market

• 24.1. USA Bioengineered Protein Drugs Market Overview
• 24.2. USA Bioengineered Protein Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Bioengineered Protein Drugs Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Bioengineered Protein Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Bioengineered Protein Drugs Market

• 25.1. Canada Bioengineered Protein Drugs Market Overview
• 25.2. Canada Bioengineered Protein Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Bioengineered Protein Drugs Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Bioengineered Protein Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Bioengineered Protein Drugs Market

• 26.1. South America Bioengineered Protein Drugs Market Overview
• 26.2. South America Bioengineered Protein Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Bioengineered Protein Drugs Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Bioengineered Protein Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Bioengineered Protein Drugs Market

• 27.1. Brazil Bioengineered Protein Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Bioengineered Protein Drugs Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Bioengineered Protein Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Bioengineered Protein Drugs Market

• 28.1. Middle East Bioengineered Protein Drugs Market Overview
• 28.2. Middle East Bioengineered Protein Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Bioengineered Protein Drugs Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Bioengineered Protein Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Bioengineered Protein Drugs Market

• 29.1. Africa Bioengineered Protein Drugs Market Overview
• 29.2. Africa Bioengineered Protein Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Bioengineered Protein Drugs Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Bioengineered Protein Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Bioengineered Protein Drugs Market Competitive Landscape And Company Profiles

• 30.1. Bioengineered Protein Drugs Market Competitive Landscape
• 30.2. Bioengineered Protein Drugs Market Company Profiles
  • 30.2.1. Abbvie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer HealthCare Pharmaceuticals LLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis

31. Bioengineered Protein Drugs Market Other Major And Innovative Companies

• 31.1. F. Hoffmann-La Roche AG
• 31.2. GlaxoSmithKline plc
• 31.3. Johnson & Johnson
• 31.4. Novartis AG
• 31.5. Novo Nordisk A/S
• 31.6. Sanofi S.A.
• 31.7. Grifols S.A.
• 31.8. Adma Biologics Inc.
• 31.9. CSL Limited
• 31.10. Abbott Laboratories
• 31.11. Baxter International Inc.
• 31.12. Fresenius Kabi AG
• 31.13. Merck & Co. Inc.
• 31.14. Pfizer Inc.
• 31.15. Biogen Inc.

32. Global Bioengineered Protein Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Bioengineered Protein Drugs Market

34. Recent Developments In The Bioengineered Protein Drugs Market

35. Bioengineered Protein Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Bioengineered Protein Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Bioengineered Protein Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Bioengineered Protein Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer